A Phase 4 interventional study of QLETLI in Uveitis, sponsored by Bio-Thera Solutions. Completed at 7 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Bio-Thera Solutions · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Uveitis with a site in China — 7 open to participants now, 9 under way, none of them phase 3. Uveitis · China.
Among the 28 studies in Uveitis with a site in China, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2021, is one of 4 in phase 4, and was the 14th registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →7 of the 28 studies in Uveitis with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18–70
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Tianjin Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 23 Uveitis studies recruiting now, 14 (61%) set no upper age limit and 9 (39%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 4 · Phase 4 4
First in 2009; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 30 across the 20 interventional studies, 160 across the 8 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 28 have an industry lead sponsor. The 10 most frequent:
Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.
Bio-Thera Solutions has 1 study filed under Uveitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Uveitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07552012Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Uveitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
Screening period (-2\~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same time, plasma concentration will be determined
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
Screening period (-2\~0 weeks) : the inclusion and exclusion criteria were evaluated, and those meeting the criteria could enter the treatment period.
Treatment period (1-22 weeks) : Eligible subjects with non-infectious uveitis were given an initial subcutaneous injection of 80 mg at week 1, followed by a subcutaneous injection of 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (a total of 12 doses).
Follow-up period: Follow-up for safety and/or efficacy is recommended at 6, 12, 24, and 32 weeks after initiation of the study drug. A final visit will be made at 32 weeks. During the study, if the condition of the subjects or their symptoms and signs become worse, the investigator can adjust the use of drugs for uveitis other than study drugs according to the actual situation of the subjects.
At the same time, plasma concentration will be determined before D1, D78 (week 12), and D162 (week 24); Immunogenicity analysis was performed before D1 administration, before D78 (week 12), before D162 (week 24) and before D218 (week 32)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects meet any of the following criteria associated with latent or active tuberculosis (TB) infection:
. A history of active TB ≤ 3 years before screening (but can also be included if it is > 3 years and documented completion of adequate treatment); B. Signs or symptoms suggestive of active TB at the time of screening in the history and/or physical examination; C. Recent close contact with someone with active TB; D. If a TB infection T-cell test is positive at the time of screening, subjects will be excluded from the study if their first TB infection T-cell test is inconclusive. For suitable standards has been completed before screening latent TB treatment and no other risk factors, imaging findings, or support the latent or signs of active TB specific subjects, for positive or uncertain results may be the exception handling, researchers with the qualified physician judgment, tuberculosis (including extrapulmonary) risk, decision and discuss with bidders;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Drug: QLETLI
80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Duration of treatment failure
Duration of treatment failure at 6 weeks of treatment or between 6 and 24 weeks of treatment (treatment failure is defined as meeting at least one of the following conditions in at least one eye:
Time frame: 6\12\24week
treatment failure rate
Treatment failure rate at each visit point from first administration to 24 weeks.Treatment failure was defined as meeting at least one of the following conditions in at least one eye: newly active inflammatory choroiditis or retinal vasculopathy \[from baseline\]; The anterior chamber cell grading or vitreous opacity grading did not reach ≦0.5+ during the 6 weeks visit, or the optimal condition did not improve in all visits after 6 weeks. Best corrected visual acuity decreased by ≧15 letters compared to best condition
Time frame: 6/12/24week
Changes in ocular inflammation
changes in anterior chamber cell grade
Time frame: 6/12/24week
Changes in ocular inflammation
changes in vitreous turbidity
Time frame: 6/12/24week
Changes in ocular inflammation
changes in macular edema
Time frame: 6/12/24week
Changes in ocular inflammation
changes in central retinal thickness
Time frame: 6/12/24week
Changes in visual acuity
Changes in visual acuity
Time frame: 6/12/24week
Changes in visual function scale VFQ-25
Changes in visual function scale VFQ-25
Time frame: 6/12/24week
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Aug 2025, 43 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2024 → Aug 2025 and completion Dec 2024 → Aug 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.